US · Healthcare · Medical Instruments & Supplies
EPS came in at 0.58 against a street estimate of 0.51 — a beat of 13.7%.
Analysts rate Baxter International Inc a hold (2 buy, 12 hold, 1 sell out of 15) with an average price target of $27.92.
CONFIDENT Baxter delivered broad-based third-quarter growth, exceeded expectations, raised 2026 guidance, and reported strong cash flow, while injectables quality issues and cephalosporin discontinuation remain key risks. Q3 FY26 Both U.S. and international markets contributed to growth; management said U.S. hospital capital spending remained stable and international drug-compounding demand was strong. Analysts focused on Round Lake’s warning letter, cephalosporin discontinuation, future margins, injectables supply, Advanced Surgery growth, tariffs and M&A. Management emphasized simplification, remediation, operating improvement and disciplined capital allocation. 2026-10-29…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 15.83% |
| Pzena Investment Management, LLC | 12.63% |
| Dodge & Cox | 11.29% |
| FMR Inc | 10.43% |
| Vanguard Capital Management, LLC | 6.53% |
| Vanguard Portfolio Management, LLC | 4.65% |
| State Street Corp | 3.98% |
| Greenhaven Associates Inc | 2.76% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 net sales were $2,976 million, up from $2,835 million in the third quarter of 2025. • Nine-month 2026 net sale | 2026-10-29 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 sales were $2.98 billion, up 5% on both a reported and organic basis. • U.S. sales were approximately $1.6 bil | 2026-10-29 |
| Board / officer change · Q3 2026 BAXTER INTERNATIONAL INC. – 8-K SUMMARY HEADLINE NUMBERS • New CFO appointment effective October 1, 2026: John Rogers joins as Executive Vice Presid | 2026-08-19 |
| Material agreement · Q3 2026 BAXTER INTERNATIONAL INC. - FORM 8-K SUMMARY August 18, 2026 --- HEADLINE NUMBERS • Company increased aggregate purchase price cap for debt tender | 2026-08-18 |
| Board / officer change · Q3 2026 BAXTER INTERNATIONAL INC. - 8-K SUMMARY OTHER NOTABLE POINTS • Executive Departure: Interim Chief Financial Officer Anita Zielinski resigned effecti | 2026-08-04 |
| Company announcement · Q3 2026 BAXTER INTERNATIONAL INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company announced cash tender offers on August 4, 2026 to repurchase up to $500 mill | 2026-08-04 |
| Quarterly report · Q2 2026 BAXTER INTERNATIONAL INC. - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Q2 2026 Net Sales: $2,960 million (up 5.3% vs. $2,810 million in Q2 2025) • Six- | 2026-07-30 |
| Quarterly report · Q1 2026 BAXTER INTERNATIONAL INC. - Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Net sales: $2,701 million (Q1 2026) vs. $2,625 million (Q1 2025) — up 2.9% • Ope | 2026-04-30 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.01 / share ex-date Nov 27, 2026 · pay Jan 4, 2027 | 2026-11-27 |
| Dividend | $0.01 / share ex-date Aug 28, 2026 · pay Oct 1, 2026 | 2026-08-28 |
| Dividend | $0.01 / share ex-date May 29, 2026 · pay Jul 1, 2026 | 2026-05-29 |
| Dividend | $0.01 / share ex-date Feb 27, 2026 · pay Apr 1, 2026 | 2026-02-27 |
| Dividend | $0.01 / share ex-date Nov 28, 2025 · pay Jan 2, 2026 | 2025-11-28 |
| Announcement | Date |
|---|---|
| Quarterly cash dividend of $0.01 per share declared, payable January 4, 2027 Baxter International’s board declared a quarterly cash dividend of $0.01 per common share. Investors listed as shareholders on November 27, 2026 will receive the payment on January 4, 2027. | 2026-10-29 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Baxter International Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.